Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes(University of California, Irvine), Collin Vu(University of California, Irvine), Jose J. Limon(Cedars-Sinai Medical Center), S. Tiong Ong(National University of Singapore), Marina Konopleva(Albert Einstein College of Medicine), Raymond J. Lim(University of California, Los Angeles), Christian Rommel(Intel (United States)), Sharmila Mallya(University of California, Irvine), Lomon So(University of Washington), Melissa A Chavez(University of California, Irvine), Yi Liu(Shenyang University of Chemical Technology), Jing Chen(Heilongjiang University of Chinese Medicine), Michael B. Lilly(Medical University of South Carolina), Michael Martin(Intel (United States)), Pingda Ren(Intel (United States))
Cited by 338
Related Papers
The translational landscape of mTOR signalling steers cancer initiation and metastasis
|Nature|2012|1.4k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|616